Ex vivo stimulation of renal tubular p-aminohippurate transport by dexamethasone and triiodothyronine in human renal cell carcinoma

被引:6
作者
Fleck, C [1 ]
Bachner, B
Göckeritz, S
Karge, E
Strohm, U
Schubert, J
机构
[1] Univ Jena, Inst Pharmacol & Toxicol, D-07740 Jena, Germany
[2] Univ Jena, Dept Urol, D-6900 Jena, Germany
来源
UROLOGICAL RESEARCH | 2000年 / 28卷 / 06期
关键词
renal tubular transport; p-aminohippurate; stimulation; renal cell carcinoma; dexamethasone; triiodothyronine;
D O I
10.1007/s002400000142
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This paper is the third of a long-term planned series of papers dealing with ex vivo investigations of drug transport in human kidney. The aims of this study are (a) to investigate whether or not human renal cell carcinoma (RCC) can actively accumulate p-aminohippurate (PAH) and (b) to test the response of RCC on dexamethasone or triiodothyronine (T3) using tissue slices ex vivo. By this approach, the accumulation capacity of RCC should be stimulated as a prerequisite for an increased uptake of anti-tumour drugs. Tissue slices of RCC samples of 30 patients were incubated for 24 h in Williams medium E containing 0.01-50 muM dexamethasone or T3. Thereafter, slices were placed in PAH-containing Cross-Taggart medium, and PAH uptake into kidney tissue was measured for 2 h under standardised conditions as described previously. In intact human renal cortical slices, PAH uptake capacity, expressed as slice to medium ratio (Q(S/M)), was about 2.8 +/- 0.16 after 24 h of incubation and increased significantly in dexamethasone-containing medium in a concentration-dependent manner, up to similar to 150%, whereas T3 did not influence PAH accumulation. On the other hand, in RCC the PAH accumulation capacity was completely abolished (Q(S/M)similar to1). However, after administration of dexamethasone, the accumulated amount of PAH increased significantly in RCC tissue in a concentration-dependent manner, up to similar to 190%. T3 was without effect in RCC, too. Surprisingly, the dexamethasone-mediated stimulation could be differentiated into responders and non-responders, with maximal effects at different concentrations for each patient. Nevertheless, the maximal transport rates remained low in RCC, even under hormone influence. In conclusion, a moderate stimulation of tubular transport capacity can be shown ex vivo in human RCC. This phenomenon is only of a relatively low degree compared with intact renal tissue. However, in principle, the response of RCC on dexamethasone could form a basis for further therapeutic strategies to overcome multi-drug resistance in RCC patients. For this purpose, additional experiments analysing the expression of transporters of the ABC cassette-type are in progress.
引用
收藏
页码:383 / 390
页数:8
相关论文
共 36 条
[11]   Intrinsic drug resistance in primary and metastatic renal cell carcinoma [J].
Gamelin, E ;
Mertins, SD ;
Regis, JT ;
Mickley, L ;
Abati, A ;
Worrell, RA ;
Linehan, WM ;
Bates, SE .
JOURNAL OF UROLOGY, 1999, 162 (01) :217-224
[12]   FLUOROMETRIC METHOD FOR DETERMINATION OF OXIDIZED AND REDUCED GLUTATHIONE IN TISSUES [J].
HISSIN, PJ ;
HILF, R .
ANALYTICAL BIOCHEMISTRY, 1976, 74 (01) :214-226
[13]   Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? [J].
Hofmockel, G ;
Bassukas, ID ;
Wittmann, A ;
Dammrich, J .
BRITISH JOURNAL OF UROLOGY, 1997, 80 (01) :11-17
[14]  
KRETZSCHMAR M, 1989, Z VERSUCHSTIERKD, V32, P41
[15]   ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2 [J].
Leier, I ;
Hummel-Eisenbeiss, J ;
Cui, YH ;
Keppler, D .
KIDNEY INTERNATIONAL, 2000, 57 (04) :1636-1642
[16]   ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump [J].
Leier, I ;
Jedlitschky, G ;
Buchholz, U ;
Center, M ;
Cole, SPC ;
Deeley, RG ;
Keppler, D .
BIOCHEMICAL JOURNAL, 1996, 314 :433-437
[17]  
LICHT T, 1995, CYTOKINES MOL THER, V1, P11
[18]  
Liu CX, 2000, CANCER RES, V60, P1961
[19]  
Meyer N, 1999, ANTICANCER RES, V19, P1509
[20]   A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections [J].
Moran, E ;
Larkin, A ;
Doherty, G ;
Kelehan, P ;
Kennedy, S ;
Clynes, M .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (06) :465-471